Australian Trial in Acute Hepatitis C (ATAHC)
A prospective non-randomised dual arm longitudinal cohort of newly acquired hepatitis C
infection into which participants will be enrolled and then followed at 3 monthly intervals
over a 3 year period.
All participants will be offered a 24 week course of pegylated interferon alfa 2a which will
be commenced within 12 weeks of screening (patients coinfected with HIV will be offered 24
weeks with pegylated interferon alfa 2a plus ribavirin).
Phase:
Phase 4
Details
Lead Sponsor:
Kirby Institute
Collaborators:
National Institutes of Health (NIH) The University of New South Wales